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Abstract: Background: People who abuse substances are at increased risk of metabolic syndrome and
diabetes resulting partly from increased cell damage and due to the effects of opioids on glucose
homeostasis. Therefore, people with diabetes who abuse substances may carry greater health risks
than the general population resulting from their effect on glucose metabolism. These substances
may be in the form of cannabis, hallucinogens, opioids, and stimulants. Therefore, the aim of this
review was to evaluate the effects of substance abuse on blood glucose parameters in patients with
diabetes. Method: Databases including Embase, Psycho-Info, Google Scholar and PubMed were
searched systematically for relevant articles from database inception to May 2018. Search terms
including medical subject headings (MeSH) based on the Population, Intervention, Comparator
and Outcomes (PICO) framework was used to access the databases. Eligible articles were selected
based on set inclusion and exclusion criteria. The articles reviewed were evaluated for quality and
meta-analysis and sensitivity analysis were carried out using the Review Manager (RevMan 5.3,
The Cochrane Collaboration, Copenhagen, Denmark). The Random effects model was used for the
data analysis. Results: Twelve studies which met the inclusion criteria were included in the systematic
review, while nine articles were selected for the meta-analysis. The results of the meta-analysis showed
that substance abuse does not have significant effects (p > 0.05) on postprandial blood glucose and
glycated haemoglobin in patients with diabetes. With respect to the effect of substance abuse on fasting
blood glucose, while this was significant (p < 0.05) following meta-analysis, the results of the sensitivity
test did not demonstrate any significant difference (p > 0.05) between patients who abused substances
compared with control. This would suggest that the effect of substance abuse on fasting blood glucose
in these patients was not very reliable or not consistent. Conclusions: The effect of substance abuse on
glycated haemoglobin and postprandial blood glucose in patients with diabetes was not significant.
In the meta-analysis, while the value was slightly lower with respect to postprandial blood glucose,
this was slightly higher in relation to HbA1c in the substance abuse group compared with control.
On the other hand, the effect of substance abuse on fasting blood glucose was significant (p = 0.03)
compared with control, but this was attenuated following a sensitivity test. A range of factors including
eating habits, characteristics of drugs, erratic lifestyle of patients may explain the outcome of this review.
There is the need for randomised controlled trials that will include diet and medication history in order
to fully understand the effect of substance abuse on blood glucose parameters in patients with diabetes.
Keywords: diabetes; substance abuse; opioids; fasting blood glucose; glycated haemoglobin;
postprandial blood glucose; meta-analysis; systematic review; blood glucose parameters
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1. Introduction
The problem of substance abuse or illicit drug addiction is worldwide and it reduces productivity
and places significant burden on healthcare systems while also negatively impacting the quality
of life of individuals and communities [1]. The illicit drugs may include cannabis, hallucinogens,
opioids, and stimulants [2]. Patients with diabetes frequently use opioids to manage diabetes-related
neuropathic pain, which may put them at increased risk of opioid use disorder [2]. Chronic opiate
use can result from opiate-related substance use disorder (SUD), or in the treatment of clinical opiate
dependence [3]. People who abuse substances are at increased risk of metabolic syndrome and diabetes
due partly to increased cell damage and lowered antioxidant potential of the cells [4]. It could also be
due to the effects of opioids on glucose metabolism and opioid users’ poor diet choices [2]. Therefore,
people with diabetes who abuse substances may carry greater health risks than the general population
resulting from their effect on glucose metabolism [5]. In a study conducted in North Carolina, USA,
adults with type 2 diabetes were found to have significantly higher rates of SUD (4.2%) compared with
those without diabetes (2.1%) [2].
The effect of opium and other illicit substances on blood glucose parameters in patients with
diabetes may be profound. In a review by Sharma and Singh Balhara [4], it was reported that among
49 patients with type 2 diabetes, it was found that the smoking of opium increased serum glucose and
increased the risk of diabetic complications. In these patients who abuse opioid, the insulin secretory
islet cells may not be responding appropriately to the glucose signals [4].
There have also been reported interactions between antidiabetic agents and prescribed, illicit and
recreational drugs [5]. People who abuse substances are at greater risk of poorer diabetes outcomes
including patient-related factors such as limited access to care, poor follow-up and suboptimal
self-management skills [6–8]. There are also clinician factors including having negative views of
patients with drug use and this may affect the quality of care that is provided for patients with
diabetes [6].
There is evidence which shows that the use of illicit drugs including opioid is associated with
glucose dysregulation, increased preference for sweet food, weight gain and the development of acute
and chronic complications [2,9].
2. Why is the Review Important?
According to Sheldon and Quin [10], regular illicit drug use may hasten the onset of type 2 diabetes
and it is associated with decreased insulin sensitivity. It has been shown that patients with co-occurring
type 2 diabetes and illicit SUD do not comply as much with guidelines for laboratory testing (glycated
haemoglobin) and clinical examinations (nephrology testing, eye examinations) and are more likely to
experience lower-limb amputations and diabetes-related hospitalizations compared to patients with
type 2 diabetes alone [2]. While substance use may play a role in type 2 diabetes outcomes, this is often
overlooked from both research and clinical perspectives [2].
Therefore, the need for researchers to direct their interest in this area is becoming more important
as the prevalence of diabetes is increasing globally [7]. A better understanding of approaches to
managing SUD in patients with or at risk of type 2 diabetes may improve health outcomes in
this high-risk population [2]. Areas of research interest could focus on determining the cause or
directionality with respect to the high rate of type 2 diabetes in adults with opioid use disorder and
the effect of substance abuse in patients with type 2 diabetes [2]. This is because there has been little
research on the role of illicit SUD and diabetes outcomes [2].
The nature of illicit drug use and the often complicated lifestyles of those patients involved may
contribute to the low level of research in this area and may make accurate assessment difficult [10].
However, the negative effects on morbidity, mortality and health economics suggest that it is a
significant problem in diabetes practice [10]. The importance of managing SUD in patients with
diabetes is underscored by the treatment guidelines recommended by the American Diabetes
Association including limiting exposure to adverse lifestyle factors, the use of pharmacotherapies,
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managing psychosocial and behavioural factors, and treating comorbid conditions, including substance
use disorders [2,7].
There are conflicting reports of the effect of substance abuse on blood glucose parameters
including glycated haemoglobin (HbA1c) levels in patients with diabetes. While studies have indicated
that nonopioid-dependent patients with diabetes demonstrate lower level of glycated haemoglobin
compared with opioid-dependent individuals [11], there is evidence showing no significant change in
the level of HbA1c in individuals with diabetes with or without opioid dependence [4,12]. However,
in some Asian countries, opium is believed to have positive impact in lowering blood glucose [13].
Following a review of the literature, the authors of this review found no evidence of any systematic
review and meta-analysis of the effects of substance abuse on blood glucose parameters in patients
with diabetes. Therefore, the aim of this review is to evaluate the effects of substance abuse on blood
glucose parameters in patients with diabetes.
Research Question: What effect does substance abuse have on markers of glycaemic control in
patients with diabetes?
3. Method
This was a systematic review and meta-analysis conducted in accordance with established
guidelines [14,15].
3.1. Data Sources and Search Strategy
Databases including Embase, Psycho-Info, Google Scholar and PubMed were searched
systematically for relevant articles from database inception to May 2018. Search terms including
medical subject headings (MeSH) based on the Population, Intervention, Comparator and Outcomes
(PICO) framework (Table 1) was used to access the databases [14]. The search terms were combined
using Boolean operators (AND/OR). All articles retrieved from the databases were exported to
EndNote (Analytics, Philadelphia, PA, USA) for de-duplication.
Table 1. Search Terms and Search Strategy.
Patient/Population Intervention Comparator Outcomes of Interest Combining Search Terms
Patients with diabetes Substance Abuse Outcomes of interest
Type 2 diabetes OR Type 1 diabetes
OR Diabetes complications OR
Diabetes mellitus, type 2 OR
Diabetes mellitus, type 1 OR
Diabetes mellitus
Substance-Related Disorders OR
substance * OR Marijuana Abuse
OR Amphetamine-Related
Disorders OR Cocaine-Related
Disorders OR Opioid-Related
Disorders OR opiate * OR opioid *
OR Heroin Dependence
Glycated hemoglobin OR
Fasting blood glucose OR
Post-prandial blood
glucose OR Fasting insulin
OR Fructosamine
Column 1 AND Column 2
AND Column 3
* (Truncation symbol).
3.2. Study Selection
Identification of relevant articles, screening of articles using the abstracts and titles were conducted
separately by the four researchers (O.O., X.-H.W., O.O.O. and J.I.) (Figure 1). In addition, eligibility of
articles using the full-text was also based on a previously agreed inclusion and exclusion criteria by
the four researchers. Differences were resolved among the researchers through consensus.
The records of articles accessed after de-duplication was 543. Following screening of the articles
using the abstract and applying the exclusion and inclusion criteria, only 12 articles were eligible for
the systematic review and nine articles for the meta-analysis.
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Figure 1. Prisma flow chart.
3.3. Eligibility Criteria
The criteria for inclusion were: (1) Patients with type 1 or type 2 diabetes who are substance
abusers; (2) Case-control study, Cross-sectional study and Retrospective cohort study; (3) Articles
written in English. Exclusion criteria were: (1) Subjects with gestational diabetes; (2) Outcomes without
blood glucose parameters.
3.4. Data Extraction
The data were extracted separately from the studies included by two researchers (O.O. and O.O.O.)
and cross checked by two other researchers (X.-H.W. and J.I.). Differences among researchers were
resolved by consensus. For this review, the following data were extracted (where available) from each
study; country of study, length of study, study type/design, age of participants, gender and the type of
substance abused. The blood glucose parameters of interest included were:
Fasting plasma glucose (mg/dL)
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2-Hours Postprandial blood glucose (mg/dL)
Glycated haemoglobin (HbA1c) (%).
3.5. Quality Evaluation
The articles included in this review were evaluated using the Critical Appraisal Skills Programme
(CASP) tool [16] and The Risk of Bias In Non-Randomised Studies of Interventions (RONINS-I)
assessment tool [17]. The studies were evaluated in relation to bias due to confounding; selection of
participants into the study; classification of interventions; deviations from intended interventions;
missing data; measurement of outcomes; selection of the reported result [17]. The risk of bias could be
classified as low, moderate, serious or critical [17]. One author (O.O.) assessed each study against the
criteria in the assessment tool and this was cross-checked by other researchers (X.-H.W.; O.O.O. and
J.I.). The assessments were based only on the data/information available in the studies.
3.6. Data Synthesis
The Mohammadali et al. [18] and Rahimi et al. [19] studies did not specify whether the data
presented were expressed in the form of means ± standard deviation (SD) or means ± standard error
of mean (SEM). The Rahimi et al. [19] study did not also specify the units of measurements. Therefore,
we contacted the corresponding authors, but received no response. We then calculated the SD based on
the means, sample sizes and the measures of dispersion and compared these with the results presented,
and the findings were comparable.
The Karam et al. study [11] presented the male and female results as separate findings and
were thus included in the data analysis separately. Due to the limited number of studies involving
patients with type 1 diabetes that were included in the meta-analysis, sub-group analysis could not be
conducted for the type of diabetes. However, sub-group analysis was carried out for studies involving
opium as SUD.
3.7. Statistical Analysis
The meta-analysis and sensitivity analysis were carried out using the Review Manager (RevMan
5.3, The Cochrane Collaboration, Copenhagen, Denmark) [20]. For sensitivity analysis, this was only
conducted for parameters involving more than two studies. The random effects model was used
for the data analysis of blood glucose because of the differences in the study designs of the various
articles included and a forest plot provided a graphical representation for the different outcomes of
interest. A p value of <0.05 was taken as statistically significant for the overall effect of the intervention.
In addition, the statistic I2 on a scale of 0–100% was used as the measure of heterogeneity across the
studies while a p value of 0.1 was used to determine statistical significance of heterogeneity.
4. Results
Twelve studies [11,12,18,19,21–28] met the inclusion criteria and were included in the systematic
review (Tables 2 and 3). Six of these studies [11,12,18,19,21,25] were conducted in Iran. Two studies
were conducted in USA and one each was carried out in the UK, Yemen, Spain and Australia.
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Table 2. Characteristics of the articles included in this review (N = 12).
Study Reference Country Length of Study Study Type/Design Sample Size/Description Age Gender Diabetes Type Type of Substance Abused
Azod et al., 2008 [12] Iran No data Cross-sectional study 23 opium46 non-opium Mean 55.24–60.52 years No data Type 2 DM Opium
Hosseini et al., 2011 [21] Iran 2008–2010 Cross-sectional study 228 opium228 non-opium Mean 58.9 (SD = 9.2 years) 92% male 91% were type 2 DM Opium
Isidro & Jorge 2013 [22] Spain 2005–2009 Retrospectivecohort study
52 events with substance use;
201 events without substance use Mean 29.5–36.7 years 58% male
Mostly Type 1 DM
(83.8–92.3%) Cocaine & polydrug use
Karam et al., 2004 [11] Iran No data Case-control study 23 male and 26 female opium23 male and 26 female non-opium 35–65 years 53% female Type 2 DM Opium
Lee et al., 2012 [23] Australia No data Cross-sectional survey 388 substance users116 non-users Mean 30–32 years 63–79% female Type 1 DM Different illicit drugs
Modzelewski et al., 2017 [24] USA 2004–2010 Retrospectivecase-control analysis
161 DM patients with cocaine use;
789 DM without drug use Mean 47.3 years 66% male No data Cocaine
Mohammadali et al., 2014 [18] Iran 2006–2007 Cross-sectional study 48 opium users49 non-opium users Mean 64 years >60% female Type 2 DM Opium
Rahimi et al., 2014 [19] Iran No data Cross-sectional study 179 opium users195 non-opium users Mean 53.5–58.2 years No data Type 2 DM Opium
Rezvanfar et al., 2011 [25] Iran 2009–2010 Case-control study 88 opium users144 non-opium users Mean 55–57 years All male Type 2 DM Opium
Saif-Ali et al., 2003 [26] Yemen No data Case-control study 21 khat chewers15 non Khat chewers 25–65 years All male Type 2 DM Khat
Saunders et al., 2004 [27] UK 1997–2002 Retrospective casenote analysis
9 intravenous drug users
18 non intravenous drug users Mean 33 years >75% male Type 1 DM No data
Warner et al., 1998 [28] USA 1985–1994 RetrospectiveCase-control study
27 cocaine user
85 non cocaine user Mean 28.2–29.7 years >65% female No data Cocaine
Abbreviations: DM (Diabetes Mellitus); SD (Standard deviation).
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Table 3. Blood glucose parameters among individuals with diabetes based on their substance use status.
Study Reference Participants Studied Fasting Blood Sugar 2-Hrs Postprandial Blood Glucose Random Blood Sugar Glycated Haemoglobin
Azod et al., 2008 [12]
Substance abusers 154.74 mg/dL (SD = 53.01) 247.43 mg/dL (SD = 81.09) No data 9.53% (SD = 1.21)
Non-substance abusers 190.67 mg/dL (SD = 75.19) p = 0.04 293.61 mg/dL (103.53) p = 0.06 No data 10.15% (SD = 2.43) p = 0.25
Hosseini et al., 2011 [21]
Substance abusers 160.68 mg/dL (SD = 67.71) No data No data No data
Non-substance abusers 170.72 mg/dL (SD = 67.26) p = 0.117 No data No data No data
Isidro & Jorge 2013 [22]
Substance abusers No data No data 32.8 mmol/L (SD = 14.5) 11.4% (SD = 1.8)
Non-substance abusers No data No data 30.5 mmol/L (SD = 13.6)p (No data) 11.6% (SD = 2.2) p (No data)
Karam et al., 2004 [11]
(for men)
Substance abusers 14.17 mmol/L (SEM = 1.17) No data No data 15.00% (SEM = 0.96)
Non-substance abusers 15.8 mmol/L (SEM = 1.49) p = 0.4650 No data No data 11.54% (SEM = 0.7) p = 0.0094
Karam et al., 2004 [11]
(for women)
Substance abusers 13.56 mmol/L (SEM = 1.64) No data No data 15.49% (SEM = 0.72)
Non-substance abusers 14.83 mmol/L (SEM = 1.17) p = 0.5700 No data No data 13.56% (SEM = 0.75%)p = 0.0915
Lee et al., 2012 [23]
Substance abusers No data No data No data 8.4% (SD = 2.1)
Non-substance abusers No data No data No data 7.6% (SD = 1.6)p = 0.03
Modzelewski et al., 2017 [24]
Substance abusers No data No data 480.9 mg/dL (SD = 211.8) 10.3% (SD = 2.8)
Non-substance abusers No data No data 442.1 mg/dL (SD = 226.2)p = 0.045
10.3% (SD = 2.9)
p = 0.903
Mohammadali et al., 2014 [18]
Substance abusers 172.98 mg/dL (SD = 76.73) No data No data 7.61% (SD = 1.92)
Non-substance abusers 177.57 mg/dL (SD = 54.05) p = 0.787 No data No data 8.0% (SD = 1.84)p = 0.168
Rahimi et al., 2014 [19]
Substance abusers 172.1 mg/dL (SD = 73.1) No data No data 8.5% (SD = 1.8)
Non-substance abusers 177.6 mg/dL (SD = 66.1) p = 0.440 No data No data 8.5 (SD = 2.1)p = 0.970
Rezvanfar et al., 2011 [25]
Substance abusers 140.0 mg/dL (SD = 88.0) No data No data 9.5% (SD = 2.4)
Non-substance abusers 141.0 mg/dL (SD = 64.0) p = 0.71 No data No data 11.0% (SD = 2.5)p = 0.006
Saif-Ali et al., 2003 [26]
Substance abusers No data 329.3 mg/dL (SEM = 31.9) No data No data
Non-substance abusers No data 302.6 mg/dL (SEM = 37.3) p (No data) No data No data
Saunders et al., 2004 [27]
Substance abusers No data No data No data Median10.2% (IQR = 1.96)
Non-substance abusers No data No data No data
Median
9.1% (IQR = 2.34)
p = 0.061
Warner et al., 1998 [28]
Substance abusers No data No data 593.4 mg/dL (SD = 238.9) No data
Non-substance abusers No data No data 531.1 mg/dL (SD = 185.8)p < 0.05 No data
Abbreviations: IQR (Inter Quartile Range); SD (Standard deviation); SEM (Standard Error of Mean).
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Most of the studies were either cross sectional studies (n = 5), retrospective cohort studies (n = 4)
or case control studies (n = 3). While seven of the studies involved patients with type 2 diabetes,
three studies had patients with type 1 diabetes and two studies did not state the type of diabetes
of participants.
In addition, participants in six of the studies were abusing opium, whereas cocaine was the
substance abused in three studies. One study each had Khat or different illicit drug abusers or the type
of substance abused was not stated.
The findings of the different studies with respect to substance abuse were varied. According to
Rezvanfar et al. [25], fasting blood glucose and HbA1c levels were lower in individuals with type
2 diabetes who abuse substances compared to non–abusers although the difference was not statistically
significant. In contrast, Karam et al. [11] found that, HbA1c levels for males and females were higher
in individuals with type 2 diabetes who abuse substances compared to non-abusers. Azod et al. [12]
provided a different dimension when they revealed that while opium might decrease blood glucose
temporarily, it had no clear and long-lasting effects on blood glucose and has no significant effect
on HbA1c.
There were also no significant differences in serum levels of glucose between individuals with type
2 diabetes who abuse substances compared to non-abusers in the study by Mohammadali et al. [18]
and in HbA1c between events shown and those not shown to be related to substance abuse [22].
Furthermore, Saif-Ali et al. [26] reported that chronic khat chewing does not affect serum glucose.
Therefore, it would seem that opium does not have significant effects on blood glucose
regulation [19]. Instead, drug use appears to be a significant contributor to poor glycaemic control in
young adults with type 1 diabetes [22] and cocaine users were found to have more frequent admissions
for diabetic ketoacidosis [28].
In the case of patients with diabetes who were intravenous drug abusers, there were higher rates
of diabetes complications [27] although Modzelewski et al. [24] observed that there was no association
between active cocaine use at the time of hospital admission and development of hyperglycaemic crisis.
Hosseini et al. [21] noted that, the use of opium for controlling blood glucose should not be encouraged.
The studies included in this review did not provide data on the duration and quality of substance
abused, diet history/compliance of participants and the type of diabetic medications except the study
by Mohammadali et al. [18] that provided the antidiabetic medication history of patients and the
Rezvanfar et al. [25] study that stated the mean duration (36 ± 6 months) of opium use.
4.1. Assessment of Risk of Bias of Included Studies
In terms of the risk of bias, the Modzelewski et al. [24] study demonstrated moderate risk of bias
in respect of selection of participants into the studies and in the measurement of outcomes (Figure 2).
All the other studies had low risk of bias in all the measures of assessment and had low overall risk
of bias (Figures 2 and 3). However, Modzelewski et al. [24] study’s overall risk of bias was moderate
(Figure 3).
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4.2. Effect of Substance Abuse on Fasting Blood Glucose
The results of the meta-analysis showed that substance abuse has significant effect (p = 0.03)
on fasting blood glucose in patients with type 2 diabetes (Mean Difference, −10.58; 95% CI, −19.84,
−1.32) (Figure 4a). However, a sensitivity analysis did not demonstrate significant difference (p = 0.11)
between patients with diabetes who abused substances compared to those who did not with respect to
fasting blood glucose (Figure 4b).
Int. J. Environ. Res. Public Health 2018, 15, 2691 10 of 16
Int. J. Environ. Res. Public Health 2018, 15, x FOR PEER REVIEW  10 of 16 
 
4.2. Effect of Substance Abuse on Fasting Blood Glucose 
The results of the meta-analysis showed that substance abuse has significant effect (p = 0.03) on 
fasting blood glucose in patients with type 2 diabetes (Mean Difference, −10.58; 95% CI, −19.84, −1.32) 
(Figure 4a). However, a sensitivity analysis did not demonstrate significant difference (p = 0.11) 
between patients with diabetes who abused substances compared to those who did not with respect 
to fasting blood glucose (Figure 4b). 
a. Meta-analysis 
 
b. Sensitivity analysis 
 
Figure 4. Results of Fasting Blood Glucose (mg/dL). 
4.3. Effect of Substance Abuse on Postprandial Blood Glucose 
There was no significant difference (p = 0.5) in postprandial blood glucose between patients with 
diabetes who abused substances compared with those who did not (Mean Difference, −22.71; 95% CI, 
−89.45, 44.04) (Figure 5). 
 
Figure 5. Results of Postprandial Blood Glucose (mg/dL). 
4.4. Effect of Substance Abuse on Glycated Haemoglobin 
The effect of substance abuse on glycated haemoglobin was not significantly different between 
patients with diabetes who abused substances and control, following meta-analysis (p = 0.81). The 
Lee et al. [23] study which was the only study that had patients with type 1 diabetes included in the 
HbA1c analysis may have increased the level of heterogeneity (I2 = 87%). The Lee et al. [23] study also 
had highest weight. However, a sensitivity analysis which was carried out by removing the Lee et al. 
Figure 4. Results of Fasting Blood Glucose (mg/dL).
4.3. Effect of Substance Abuse on Postprandial Blood Glucose
There was no significant difference (p = 0.5) in postprandial blood glucose between patients with
diabetes who abused substances compared with those who did not (Mean Difference, −22.71; 95% CI,
−89.45, 44.04) (Figure 5).
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4.4. Effect of Substance Abuse on Glycated Haemoglobin
The effect of substance abuse on glycated haemoglobin was not significantly different between
patients with diabetes who abused substances and control, following meta-analysis (p = 0.81).
The Lee et al. [23] study which was the only study that had patients with type 1 diabetes included
in the HbA1c analysis may have increased the level of heterogeneity (I2 = 87%). The Lee et al. [23]
study also had highest weight. However, a sensitivity analysis which was carried out by removing
the Lee et al. [23] study did not demonstrate significant difference (p = 0.80) in HbA1c levels between
patients with diabetes who abused substances compared with control. Mean Difference was 0.08 for
meta-analysis and −0.09 for sensitivity analysis (Figure 6a,b).
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A sub-group analysis for studies involving opium as SUD showed that the mean difference
between the substance abuse group and control with respect to glycated haemoglobin was −0.01
(−0.87, 0.84) and the difference was not significant (p = 0.98) (Figure 6c).
5. Discussion
The results of the meta-analysis have shown that substance abuse does not have significant
effects (p > 0.05) on postprandial blood glucose and glycated haemoglobin in patients with diabetes.
With respect to the effect of substance abuse on fasting blood glucose, while this was significant
(p < 0.05) following meta-analysis, the results of the sensitivity test did not demonstrate any significant
differ nce (p > 0.05) between pati nts who abused substances compared with control. This w uld
sug est tha the effect of substa ce abuse on fasting blood glu se in these patients was not very
reliable or not consistent.
Although there appeared to be lower levels of fasting and postprandial blood glucose and higher
level of HbA1c in the substance abuse group compared with control, these findings were not significant
and/or were not consistent. The outcomes seem to confirm the results of the current systematic review
which found that the effects of substance abuse on blood glucose parameters was variable in the
different studies. In particular, while substance abuse was found to reduce fasting blood glucose and
HbA1c in individuals with type 2 diabetes who abuse substances [25], it raised HbA1c in individuals
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with type 2 diabetes who abuse substances in another study [11]. Azod et al. [12] noted that although
opium may reduce blood glucose, it does not seem to have a long-lasting effect on blood glucose.
Both fasting and postprandial blood glucose reflect short term measures of blood glucose control
while glycated haemoglobin represents the average glycaemia over a period of 2–3 months [29].
These findings appear to reinforce the challenges faced by researchers in trying to establish the cause
and/or directionality between diabetes and substance use disorders and the controversy regarding the
role of opioids in regulating glucose homeostasis [2,30]. In this regard, while there is evidence that
opium consumption is the cause of impaired glucose tolerance and increased resistance to insulin,
other studies have also shown severe hyperglycaemia following the discontinuation of opium [25].
5.1. Factors Contributing to the Observed Differences on the Effects of Substance Abuse on Blood
Glucose Control
Sharma and Sing Balhara [4] observed that opioid dependent individuals are in a metabolic state
that resembles diabetes although the causal hypothesis has not been fully established. The differences
in the findings of the studies in this review may be partly due to differences in sample size and
the sampling methods [19,25]. In addition, opium has about 20 alkaloids, therefore, their effects
on metabolism and the endocrine system may be different compared to pure morphine, noscapine,
and papaverine and the findings may thus, vary from one study to the other [11,30]. The differences
in the findings may have also resulted from variations in the time of blood collection after the
last consumption of drug, age range of subjects, duration of drug dependency, sociodemographic
characteristics, the type of diabetes and its probable outcomes on function of liver and kidney [30].
Despite this position, only few associations were observed between the number of days of drug use
and drug use severity in relation to blood glucose control in adult patients reporting recent drug
use [6]. In the same study, cocaine use appeared to be associated with worse blood glucose control
than marijuana. The action of cocaine on alpha—adrenergic system which may lead to hyperglycaemia
has been reported as a possible mechanism of action of cocaine on blood glucose homeostasis [9].
Patients with diabetes who abuse substances may have poorer glycaemic control due to
a number of reasons including their poor nutrition state, mental illness and erratic lifestyle
such as poor compliance with prescribed medications including insulin and poor diabetic clinic
attendance [10,31,32]. In fact, the effect of poor medication management in patients with diabetes
who abuse substances could be bi-directional. For example, an overdose of insulin could lead to
hypoglycaemia while insufficient dose of the same medication could cause hyperglycaemic episode
irrespective of the underlying effect of substance abuse [33]. Opioid use can lead to sedation and
cognitive decline which could affect the patients’ ability to provide selfcare, access healthcare provisions
including diabetic tests and the potential for increased diabetes related complications [2].
Therefore, in order to assess the effect of drug use on blood glucose parameters in patients with
diabetes who abuse substances, it is essential to have information on the characteristics of the drugs
being abused and studies should not just be limited to whether the patients are abusing drugs or
not [6]. This is because the frequency, the type of drug and/or its severity may have different effects on
clinical outcomes including blood glucose parameters of patients, although these data are difficult to
obtain [6] and many of the studies in this review did not report this kind of information. In this regard,
substance abuse may contribute to the non compliance with diabetic medication including insulin [9].
5.2. The Increase in the Risk of Hyperglycaemia in Patients with Diabetes Who Abuse Opioids
According to Sharma and Sing Balhara [4], there appears to be evidence which point to the role
of opioids in glucose homeostasis. While there was evidence of some effects of SUD on glycaemia in
patients with diabetes based on the current meta-analysis, these were not significant with respect to
glycated haemoglobin and postprandial blood glucose although the effect on fasting blood glucose
was significant albeit not consistent. In a previous review [2], high rates of type 2 diabetes (25–28%) in
adults who either previously or were receiving opioid maintenance therapy was reported. The findings
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of higher prevalence of patients with type 2 diabetes in individuals who abuse opioids may be due to
the effect of opioids on glucose metabolism and the poor diet choices of opioid users [2]. Data from
studies have found that the use of opioids is associated with glucose dysregulation and worse diabetes
performance measures [2,34]. The mechanisms of action of opioids including morphine on blood
glucose homeostasis have been demonstrated in human studies and in animal models. These include
increased production of adrenocorticotrophic hormone (ACTH) and plasma adrenaline, nor-adrenalin,
cortisol and glucagon [9,11,19]. These are counter-regulatory hormones and their actions oppose that
of insulin in the facilitation of glucose into the cells [19]. According to Azod et al. [12], in animal
studies, the hyperglycaemic effect of morphine may be due to its effect on glucagon production without
corresponding release of insulin. The acute hyperglycaemic effect of morphine may be controlled by
the central nervous system causing decreased insulin secretion and glycogenolysis [13]. In patients
with diabetes, this is exacerbated due to increased glucagon production [13].
It has been observed that patients who are dependent on opioids do not respond adequately to
insulin signals thus leading to loss of glucose homeostasis [4]. However, chronic heroin administration
can produce a state of fasting hyperinsulinaemia even in the absence of glucose intolerance and may
interfere negatively with carbohydrate metabolism [35]. The hypothesis that has been suggested is
based on the possible development of fasting hyperglycaemia as a result of either insulin resistance
through a secondary down-regulation of insulin receptors or accelerated beta cell failure [35]. However,
the challenge of confirming this hypothesis reside on a number of factors including narcotic withdrawal,
intercurrent infections, eating habits and early death [35].
5.3. The Lowering of Glycaemic Parameters in Patients with Diabetes Who Abuse Opioids
It has also been reported that morphine could exert a hypoglycaemic effect at low dose infusion
when the endocrine pancreatic function is fixed at basal level [12]. The authors noted that the findings
relating to the hypoglycaemia was independent of detectable changes in insulin, glucagon, epinephrine
and suggested that the hypoglycaemic effect of morphine results from the interaction of the opiate
with non-mu receptors, either in the liver or the central nervous system.
Another possible explanation in the lowering of postprandial blood glucose in patients with
diabetes who abuse substances may be due to decrease in gastric emptying resulting from opioid
µ-receptor activation and delay in intestinal glucose absorption [13]. According to Kouros et al. [30],
increased utilisation of glucose and a decrease of hepatic gluconeogenesis resulting from the activation
of peripheral opioid µ-receptors and alterations of glucose metabolism which may be related to genes
have been proposed as possible mechanisms involved in decreasing the plasma glucose. The effects of
medication taken by patients to manage their condition and other co-morbidities may also contribute
to the lowering of blood glucose in patients with diabetes who abuse substances.
5.4. The Pharmacological Effects of SUD on Glucose Management Versus Non-Pharmacological Effects of SUD
Patients with diabetes often use opioids to manage diabetes related pains including peripheral
neuropathic pain [1,36]. About 16–20% of patients with diabetes experience chronic neuropathic
pain [36]. However, the long term treatment with opioids may lead to opioid abuse which could have
impact on glucose homeostasis [2].
In terms of illicit substance use disorder, it would appear that patients with co-occurring type
2 diabetes and illicit SUD are more likely to have lower limb amputation and diabetes related
complications compared with those with type 2 diabetes alone [2].
6. Limitations
Most of the studies included in this review were carried out in Iran, therefore, this may affect its
broader application. In addition, most of the studies did not provide data on the duration and quality
of substance abused, diet history/compliance of participants and the type of diabetic medications thus
making analysis difficult. The Mohammadali et al. [18] and Rahimi et al. [19] studies did not specify
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whether the data presented were expressed as means ± SD or means ± SEM. Although the SD was
calculated based on the means, sample sizes and measures of dispersion and were found comparable
to the results presented, the failure to properly report these measures is a limitation of those studies.
7. Conclusions
The effect of substance abuse on glycated haemoglobin and postprandial blood glucose in patients
with diabetes was not significant. However, while the value was slightly lower with respect to
postprandial blood glucose, this was slightly higher in relation to HbA1c in the substance abuse group
compared with control. On the other hand, the effect of substance abuse on fasting blood glucose
was significant (p = 0.03) compared with control, but this was attenuated following a sensitivity test.
This would suggest that the effect of substance abuse on fasting blood glucose is not very reliable or
is transient. A range of factors including narcotic withdrawal, intercurrent infections, eating habits,
characteristics of drugs, erratic lifestyle of patients may explain the outcome of this review. There is
the need for randomised controlled trials that will include diet and medication history in order to fully
elucidate the effect of substance abuse on blood glucose parameters in patients with diabetes.
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